BioCentury | Oct 29, 2020
Product Development

Gilead leaning on cancer deals for growth as filgotinib’s future hangs in the balance

As it awaits more clarity on a path forward for autoimmune candidate filgotinib, Gilead is leaning on its recent spate of cancer deals, most notably with ADC developer Immunomedics, for near-term growth.  Filgotinib, the centerpiece of...
BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

Through its latest deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market. EQRx Inc. launched in January with a $200 million series A and a mission to bring innovative...
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

Ultragenyx, Solid Bio in deal for DMD gene therapyUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is collaborating with Solid Biosciences Inc. (NASDAQ:SLDB) to develop a gene therapy for Duchenne muscular...
BioCentury | Oct 22, 2020
Product Development

Data Byte: AbbVie’s oral JAK takes the lead in coming competition for Dupixent in atopic dermatitis

Phase III data for coming entrants to the atopic dermatitis market show Rinvoq upadacitinib from AbbVie Inc. (NYSE:ABBV) has the edge in efficacy, compared with three other Phase III programs and the marketed therapy Dupixent...
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease. But a patient death raises the possibility allogeneic...
BioCentury | Oct 17, 2020
Translation in Brief

SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more

SARS-CoV-2 infects brain choroid plexusA team from Medical Research Council Laboratory of Molecular Biology (MRC LMB) have found that SARS-CoV-2 infects the CSF-producing brain choroid plexus — but not...
BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

EMA’s CHMP has backed autologous cells therapies Tecartus, from Gilead, and Lebmeldy, from Orchard, in its October set of opinions. The agency recommended conditional marketing approval for Tecartus brexucabtagene autoleucel from the Kite Pharma Inc....
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

RayzeBio thinks its targeting and radioisotope strategies can take radiopharmaceuticals from  a series of individual success stories to a broadly applicable platform technology for cancer. The company...
BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

The failure of Gossamer’s lead program in two Phase II trials continues to sow doubts about the efficacy of drug candidates targeting PTGDR2, but the company believes further analysis of one study’s data still points...
BioCentury | Oct 13, 2020
Deals

Launched by Mazumdar-Shaw, Parmar and Mukherjee, Immuneel takes step toward $50,000 CAR T for India

Immuneel, a Bangalore start-up dedicated to making cancer cell therapies available in India at prices far below those charged in developed countries, announced Tuesday its first step to bring CAR T treatments to the subcontinent. Immuneel Therapeutics...
Items per page:
1 - 10 of 12572